PD Dr. Benjamin Heidrich participates in RESIST research project B11.

My Research Interest in RESIST

Our research focus in RESIST is the susceptibility to cholangitis and individual treatment approaches in primary sclerosing cholangitis (PSC) before and after liver transplantation (LTX) (SusTreat-PSC). The biliary tract was considered to be a sterile niche. However, we and others could show that even in healthy individuals there is an existing biliary microbiota. Patients with PSC are at high risk to develop bacterial cholangitis often chronic recurrent cholangitis leading to chronic liver failure and the need of liver transplantation.

Within RESIST we are interest to define the bacteria and their specific mechanisms being involved in the development of bacterial cholangitis. With the knowledge we plan to improve the recommendations regarding antibiotic therapies, define new treatment approaches for targeted therapies and implement screening methods for patients at risk of bacterial cholangitis.

Contact

Prof. Heidrich about his scientific work

PD Dr. Benjamin Heidrich – Curriculum Vitae

Current Position

  • Since 2018 Consultant for Internal Medicine and Junior Research Group Leader 

Undergraduate and Postgraduate Training

  • 2002 – 2009 Hannover Medical School 

  • 2010 Medical Doctorate (Dr. med.; Supervisor Prof. Dr. med. H. Wedemeyer)

  • 2018 Certificate of Completed Specialist Training in Internal Medicine 

  • 2019 Habilitation (Supervisor Prof. Dr. med. H. Wedemeyer/ Prof. Dr. med. M. Manns)

Academic and Research Posts

  • 2009 – 2018 Fellow in the Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany

  • 2011 – 2012 Fellow in the “Integrated Research and Treatment Center Transplantation (IFB-TX)”, Hannover Medical School

  • 2014 – 2015 Clinical Leave Stipend of the German Center for Infection Research (DZIF), Helmholtz Center for Infection Research, Braunschweig, Germany

  • Since 2016 Junior Research Group Leader, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School

Other Scientific Roles

  • 2010 – 2015 Managing Secretary Hepatitis Delta International Network, Coordinator: Prof. Dr. Heiner Wedemyer

  • 2011 – 2018 Study Coordinator and Medical Advisor „Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II)”, Hannover Medical School

  • 2017 – 2019 Member in the Clinician Scientist Program of the „Junge Akademie MHH“.

  • Since 2019 Co-Cordinator for the TTU Gastrointestinal Infection in the German Center for Infection Research (DZIF) and Head of Centre for Gastrointestinal Clinical Studies (CEGICLIN)

  • Since 2019 Deputy spokesperson and Principle Investigator in the PRESENt consortium (Paving the Way towards Personalized Prevention and Care of Severe Norovirus Gastroenteritis

Awards and Prizes

  • 2008 Young Investigator Full travel bursary EASL International Liver Congress Milan 2008

  • 2008 Travel Award Glaxo Smith Kline Stiftung International Liver Meeting in San Francisco

  • 2013 Young Investigator Full travel bursary EASL International Liver Congress Amsterdam

  • 2014 Young Investigator Registration bursary EASL International Liver Congress London 2014

  • 2014 Travel Award DGIM Internistenkongress der DGIM Wiesbaden 2014

  • 2015 Young Investigator Full travel bursary EASL Monothematic Conference on Microbiota, Metabolism and NAFLD in Innsbruck 2015

Recommended Links

For further information about PD Heidrich’s scientific work please check the following links:

10 Selected Publications

Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH,  and Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scandinavian Journal of Gastroenterology July 2019 (accepted)

Schlegel T, Schallert K, Vilchez-Vargas R, Benndorf D, Püttker S, Sydor S, Schulz C, Bechmann L, Canbay A, Heidrich B, Reichl U, Link A, Heyer R. Metaproteomics of fecal samples of Crohn’s Disease and Ulcerative Colitis. J Proteomics. 2019 Apr 19. pii: S1874-3919(19)30113-7.

Wedemeyer H*, Yurdaydin C*, Hardtke S, Caruntu FS, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, for the HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019 Mar;19(3):275-286

Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Mann MP, Dienes HP, Falk C, Wedemeyer H, Heidrich B. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. J Viral Hepat. 2018 Nov;25(11):1384-1394.

Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Philipp S, Lenzen H, Potthoff A, Manns MP, Wedemeyer H, and Pieper DH. Intestinal microbiota in patients with chronic hepatitis C with and without liver cirrhosis compared to healthy controls. Liver Int. 2018 Jan;38(1):50-58.

Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017 May 15;5(1):54.

Wranke A, Calle Serrano B, Heidrich B, Kirschner J, Bremer B, Lehmann P, Hardtke S, Deterding K, Port K, Westphal M, Manns MP, Cornberg M, Wedemeyer H. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017 Feb;65(2):414-425.

Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. Non-Invasive Fibrosis Score for Hepatitis Delta. Liver Int. 2017 Feb;37(2):196-204.

Heidrich B, Steinmann E, Plumeier I, Kirschner J, Sollik L, Ziegert S, Engelmann M, Lehmann P, Manns MP, Pieper DH, and Wedemeyer H. Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. J Clin Virol. 2016 Jul;80:1-7.

Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, and Wedemeyer H for the HIDIT-1 Study group. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. Hepatology. 2014 Jul;60(1):87-97.

Contact

  PD Dr. Benjamin Heidrich
  Klinik für Gastroenterologie, Hepatologie and Endokrinologie
  Carl-Neuberg-Str. 1
30625 Hannover
  0176 – 1 – 5322849
  Heidrich.Benjamin@mh-hannover.de